Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook

Biolase Receives Eye Treatment Patent

Facebook Twitter LinkedIn Email Comments
IRVINE, Calif., Sept. 12, 2011 — Dental laser manufacturer Biolase Technology Inc. has received US Patent No. 7,997,279, titled “Methods for Treating Eye Conditions,” from the US Patent and Trademark Office, the company announced recently.

The new patent is the 13th issued in the ophthalmic family, with 20 others pending. It continues and expands US Patent No. 7,665,467, with broad claims covering the use of laser technology for treating various conditions of the eye, including presbyopia — the inability to focus sharply for near vision — and it opens up opportunities in oculoplastics as well as the treatment of cataracts and glaucoma.

In other news, the company has formed a Oculase Inc., a wholly owned subsidiary based in Delaware. The new entity will own and develop the company’s ophthalmic assets and technologies. Biolase said it plans to develop an operating unit at the new venture to focus specifically on diseases and conditions of the eye.

For more information, visit:
Sep 2011
The branch of medicine involved in the study of the anatomy, functions, diseases and treatments of the eye.
A state in which the human eye has very little or no power of accommodation. A common and normal condition in the eyes of those age 50 and older.
Americasbiolase technologyBiophotonicsBusinessCaliforniacataractsDelawaredental laserseye diseaseglaucomaOculaseoculoplasticsophthalmic stentsophthalmologypresbyopiaUS Patent No. 7665467US Patent No. 7997279lasers

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2020 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, [email protected]

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.